Stephanie Tozzo
Chief Tech/Sci/R&D Officer bij Avilar Therapeutics, Inc.
Vermogen: - $ op 31-03-2024
Profiel
Stephanie Tozzo currently works at Avilar Therapeutics, Inc., as Chief Science Officer & Senior Vice President from 2021.
Dr. Tozzo also formerly worked at CohBar, Inc., as Director from 2022 to 2023.
Dr. Tozzo received her graduate degree from Université Paris-Saclay.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
COHBAR INC
-.--% | 15-08-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Stephanie Tozzo
Bedrijven | Functie | Begin |
---|---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Chief Tech/Sci/R&D Officer | 01-11-2021 |
Eerdere bekende functies van Stephanie Tozzo
Bedrijven | Functie | Einde |
---|---|---|
COHBAR, INC. | Director/Board Member | 10-11-2023 |
Opleiding van Stephanie Tozzo
Université Paris-Saclay | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
COHBAR, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |